Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is -31.32% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROIC needs at least three reported quarters before a meaningful chart is shown.
RETURN ON INVESTED CAPITAL (ROIC)
-31.32%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
+12.13%
vs the sector median at left
Starling Oncology, Inc.
Market Cap
$658.53M
Return on Invested Capital (ROIC)
-31.32%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$654.74M
Return on Invested Capital (ROIC)
-90.42%
TTM Avg
-73.13%
3Y Avg
-82.56%
5Y Avg
-61.25%
Market Cap
$662.48M
Return on Invested Capital (ROIC)
1.97%
TTM Avg
18.16%
3Y Avg
11.04%
5Y Avg
1.26%
Market Cap
$663.91M
Return on Invested Capital (ROIC)
-44.30%
TTM Avg
-32.94%
3Y Avg
-36.44%
5Y Avg
-31.30%
Market Cap
$665.98M
Return on Invested Capital (ROIC)
-73.27%
TTM Avg
-60.64%
3Y Avg
-63.77%
5Y Avg
-62.42%
Market Cap
$668.94M
Return on Invested Capital (ROIC)
-101.43%
TTM Avg
-70.16%
3Y Avg
-61.78%
5Y Avg
-52.46%
Market Cap
$680.78M
Return on Invested Capital (ROIC)
-54.12%
TTM Avg
-85.96%
3Y Avg
-71.51%
5Y Avg
-63.27%
Market Cap
$634.07M
Return on Invested Capital (ROIC)
-42.02%
TTM Avg
-66.01%
3Y Avg
-48.82%
5Y Avg
-55.42%
Market Cap
$685.85M
Return on Invested Capital (ROIC)
-118.97%
TTM Avg
-130.14%
3Y Avg
-108.49%
5Y Avg
-89.69%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Starling Oncology, Inc. (STLN) | $658.53M | -31.32% | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $654.74M | -90.42% | -73.13% | -82.56% | -61.25% |
| MiMedx Group, Inc. (MDXG)vs › | $662.48M | 1.97% | 18.16% | 11.04% | 1.26% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $663.91M | -44.30% | -32.94% | -36.44% | -31.30% |
| Helus Pharma Inc. (HELP)vs › | $665.98M | -73.27% | -60.64% | -63.77% | -62.42% |
| Annexon, Inc. (ANNX)vs › | $668.94M | -101.43% | -70.16% | -61.78% | -52.46% |
| Solid Biosciences Inc. (SLDB)vs › | $680.78M | -54.12% | -85.96% | -71.51% | -63.27% |
| Aura Biosciences, Inc. (AURA)vs › | $634.07M | -42.02% | -66.01% | -48.82% | -55.42% |
| Verastem, Inc. (VSTM)vs › | $685.85M | -118.97% | -130.14% | -108.49% | -89.69% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $690.71M | -47.96% | -47.20% | -41.20% | -37.18% |
ROIC
-31.3%
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -31.32% |
